REGN

Regeneron Pharmaceuticals, Inc. News Headlines

$303.09
*  
1.35
0.44%
Get REGN Alerts
*Delayed - data as of Jul. 25, 2014  -  Find a broker to begin trading REGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Clovis Oncology Initiates Study on CO-1686 - Analyst Blog
6/24/2014 11:40:00 AM - Zacks.com

Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights - Analyst Blog
6/23/2014 4:45:00 PM - Zacks.com

RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog
6/23/2014 12:10:00 PM - Zacks.com

Perrigo Settles Patent Dispute with Teva - Analyst Blog
6/23/2014 12:00:00 PM - Zacks.com

Alnylam-TAP Collaborate for AAT Candidate - Analyst Blog
6/20/2014 4:45:00 PM - Zacks.com

Nasdaq 100 Movers: WFM, DISH
6/20/2014 12:13:57 PM - BNK Invest

Celgene Rises on Yet Another Stock Split - Analyst Blog
6/20/2014 11:30:00 AM - Zacks.com

Cubist Gets Priority Review from FDA for Antibiotic Candidate - Analyst Blog
6/20/2014 11:00:00 AM - Zacks.com

BioLineRx to Commence BL-8040 Study - Analyst Blog
6/19/2014 6:10:00 PM - Zacks.com

Insmed Soars on Arikayce's Breakthrough Designation - Analyst Blog
6/19/2014 4:30:00 PM - Zacks.com

Alkermes' Aripiprazole Lauroxil Looks Promising - Analyst Blog
6/19/2014 11:40:00 AM - Zacks.com

Should You Add To Your Holdings In These H&Q Biotechnolgy Funds?
6/18/2014 6:09:00 PM - Seeking Alpha

Alexion's Soliris Gets Orphan Drug Status for New Indication - Analyst Blog
6/18/2014 11:30:00 AM - Zacks.com

Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog
6/17/2014 5:00:00 PM - Zacks.com

Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog
6/17/2014 1:40:00 PM - Zacks.com

Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog
6/16/2014 6:10:00 PM - Zacks.com

Gilead's HCV Combination Therapy Data Looks Promising - Analyst Blog
6/16/2014 11:40:00 AM - Zacks.com

Sanofi/ Regeneron Present Postive Data on Sarilumab - Analyst Blog
6/13/2014 4:50:00 PM - Zacks.com

Exelon Moves Up In Market Cap Rank, Passing Regeneron Pharmaceuticals
6/13/2014 4:36:50 PM - BNK Invest

Vertex Pharmaceuticals' New Kalydeco Data Out - Analyst Blog
6/13/2014 4:10:00 PM - Zacks.com

Geron Gains as FDA Lifts Partial Hold on Imetelstat Study - Analyst Blog
6/13/2014 1:10:00 PM - Zacks.com

Bristol-Myers Suffers a Legal Setback - Analyst Blog
6/13/2014 11:30:00 AM - Zacks.com

Orexigen Slumps as Obesity Drug Approval Delayed - Analyst Blog
6/12/2014 6:28:00 PM - Zacks.com

Eli Lilly's Cyramza Misses Primary Goal in Liver Cancer Study - Analyst Blog
6/12/2014 5:35:00 PM - Zacks.com

Bayer Looking to Expand Eylea's Label - Analyst Blog
6/12/2014 5:00:00 PM - Zacks.com